Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

NCT03039114

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Banner Health Gilbert, Arizona, United States
  • University of California, San Diego La Jolla, California, United States
  • University of Kansas Cancer Center Fairway, Kansas, United States
  • Center for Cancer and Blood Disorders (CCBD) - Bethesda Bethesda, Maryland, United States
View all 21 locations
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

NCT05253807

Conditions
Acrocephalosyndactylia, Bone Diseases, Bone Diseases, Developmental, +25 more
Locations
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Florida Cancer Specialists & Research Institute Fort Myers, Florida, United States
  • Miami Cancer Institute Miami, Florida, United States
  • Memorial Healthcare System Pembroke Pines, Florida, United States
View all 36 locations
View Trial Details
Completed

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

NCT02628574

Conditions
Disease Attributes, Neoplasm Metastasis, Neoplasms, +5 more
Locations
  • University of Chicago Chicago, Illinois, United States
  • University of New Mexico Comprehensive Cancer Center Albuquerque, New Mexico, United States
  • University Hospitals Cleveland, Ohio, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Local Institution - 129 Scottsdale, Arizona, United States
  • Local Institution - 116 Scottsdale, Arizona, United States
  • Local Institution - 115 San Francisco, California, United States
  • Local Institution - 106 Aurora, Colorado, United States
View all 54 locations
View Trial Details
Completed

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

NCT01748149

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Mattel Children's Hospital UCLA Los Angeles, California, United States
  • Children's Hospital and Research Center at Oakland Oakland, California, United States
  • Rady Children's Hospital - San Diego San Diego, California, United States
View all 21 locations
View Trial Details
Completed

Tuberculosis (TB) Aftermath

NCT04333485

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +9 more
Locations
  • Dr. D.Y. Patil Medical College, Hospital and Research Centre Pune, Maharashtra, India
View Trial Details
Completed

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

NCT06163040

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Chang Gung Memorial Hospital- Chiayi Chiayi City, Chiayi, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
  • China Medical University Hospital Taoyuan City, Taiwan
View Trial Details

Related conditions